Melio is a health tech start-up focused on helping people unlock the secrets to their personal health through blood testing.


We provided seed finance on day one, backing a management team with deep industry expertise. We’ve subsequently participated in follow-up rounds, working with sector-specialist investors.


Melio have built a comprehensive phlebotomy (blood testing) network across the UK and Spain and have plans to roll out in other European markets.


2021 saw Melio add a specialist team of immunologists from Guy’s Hospital to their roster. They had been studying the varied response of the immune system to COVID-19.


They’re now building the world’s largest immune health platform to revolutionise medicine and prevention.


Beaumont have worked with the leadership team at Melio on their vision to setup the next generation of blood collection and analysis – ‘health biomarker analysis 2.0’.


We’ve provided extensive support and insights on marketing technology and data management, as well as broad support on general management, to allow the Melio team to drive the business forward.





Beaumont Capital

We provide Angel and Series A funding to businesses we’re passionate about and help them raise further funding.